Stay updated on Trastuzumab Emtansine in HER2+ Tumors Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page.

Latest updates to the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page revision/version string was updated from v3.5.2 to v3.5.3, reflecting a site release rather than a change to the clinical study record details.SummaryDifference0.0%

- Check19 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 from the revision history.SummaryDifference0.0%

- Check27 days agoChange DetectedLocation name updated from Padua to Padova for the Veneto, Italy site (35128).SummaryDifference0.0%

- Check48 days agoChange DetectedRevision label updated to v3.5.0 with the v3.4.3 label removed.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision labels updated: v3.4.3 added and v3.4.2 removed.SummaryDifference0.0%

- Check84 days agoChange DetectedRevision: v3.4.2 was added to the site, and the previous funding-status notice (v3.4.1) was removed.SummaryDifference0.4%

Stay in the know with updates to Trastuzumab Emtansine in HER2+ Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page.